medcelerator · clinician one-pager
First FDA-Approved Eye Form of Bevacizumab for Wet AMD
Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration
FDA Approved · United States, United Kingdom, European Union · September 11, 2026
Condition: Wet Age-Related Macular Degeneration
Who this is for
This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava monthly eye injections — the first FDA-approved ophthalmic bevacizumab made for the eye. It explains how this differs from compounded hospital Avastin, the monthly injection schedule, NORSE TWO vision results, eye-infection and pressure watchpoints, and how to talk with a retina specialist — without treating an EU/UK gamma pack as a US vikg refill, a DIY import as a plan, or NORSE EIGHT’s missed non-inferiority margin as hidden. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States and the European Union, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In the United Kingdom, authorisation is not confirmed; see Possible routes below if any are listed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf
European Union · Prescription
EU prescription (EC marketing authorisation)
https://www.ema.europa.eu/en/medicines/human/EPAR/lytenava
Possible routes (not confirmed)
United Kingdom · Prescription · Applicability unknown
UK prescription (MHRA authorisation per body)
UK authorisation is stated in the article body only; no MHRA primary page confirms it.
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
CTIS (EU Clinical Trials Information System)
European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.
https://euclinicaltrials.eu/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/lytenava-bevacizumab-vikg